There's a rumour that a deal has been done with AbbVie. If that's correct, we may get their trio of drugs at the 'right price', and Sovaldi will left out in the cold.
IMO, there is a distinct possibility that the AbbVie combo will dominate the US market as well come December, assuming it is priced less that Gilead's combo.
It is perplexing to me, from a business standpoint, that Gilead's stance has been so unyielding. Gilead could have easily taken most of the HCV market both domestically and internationally. It could have served many more people at a substantially reduced cost. Not only would the profits have been equal to or greater in the long term but Gilead could have generated a fantastic amount of goodwill. Instead Gilead has come to symbolize all that is wrong with big pharma in the US. Gilead is now consistently getting bad press, it has garnered great public disdain, and has even managed to piss off some members of Congress.
I suppose Gilead can always do a turn about by reducing prices once the competition enters the picture but a certain amount of damage has already been done. How are Gilead's actions good for the specialty pharmaceutical industry in the long term? This strikes me as extremely poor business planning and that surprises me. Perhaps Gilead is only thinking in the short term, and that concerns me, because it makes me think their product won't withstand the test of time and they know it.
longld said
Sep 3, 2014
Always admired the Aussies for their being 'up front'. They sure didn't hide behind some missing data or some such nonsense - just said it was too expensive for their people. An Aussie will never sneak up behind you - you will see (and Hear) them coming - love em! Spent many a lovely day with them in Canberra, Sydney and Melbourne.
Getting a Taxi by yourself in Sydney? - sit up front mate - love it!
-- Edited by longld on Wednesday 3rd of September 2014 05:48:33 AM
mallani said
Sep 3, 2014
Hi guys,
This is the game we play here. The TGA have approved Sovaldi, so Gilead now try to get our Federal Government to pay for it, by putting it on our PBS (Pharmaceutical Benefits Scheme). So it's submitted to the PBAC, who refuse it. In 2 months, they'll do it again. Merck submitted Victrelis 12 times before it was approved.
There's a rumour that a deal has been done with AbbVie. If that's correct, we may get their trio of drugs at the 'right price', and Sovaldi will left out in the cold.
Isiscat2011 said
Sep 2, 2014
Well, they are only Australians, after all. As long as I get mine, right?
longld said
Sep 2, 2014
Looks like Sovaldi is too expensive for Australians according to the government?
IMO, there is a distinct possibility that the AbbVie combo will dominate the US market as well come December, assuming it is priced less that Gilead's combo.
It is perplexing to me, from a business standpoint, that Gilead's stance has been so unyielding. Gilead could have easily taken most of the HCV market both domestically and internationally. It could have served many more people at a substantially reduced cost. Not only would the profits have been equal to or greater in the long term but Gilead could have generated a fantastic amount of goodwill. Instead Gilead has come to symbolize all that is wrong with big pharma in the US. Gilead is now consistently getting bad press, it has garnered great public disdain, and has even managed to piss off some members of Congress.
I suppose Gilead can always do a turn about by reducing prices once the competition enters the picture but a certain amount of damage has already been done. How are Gilead's actions good for the specialty pharmaceutical industry in the long term? This strikes me as extremely poor business planning and that surprises me. Perhaps Gilead is only thinking in the short term, and that concerns me, because it makes me think their product won't withstand the test of time and they know it.
Always admired the Aussies for their being 'up front'. They sure didn't hide behind some missing data or some such nonsense - just said it was too expensive for their people. An Aussie will never sneak up behind you - you will see (and Hear) them coming - love em! Spent many a lovely day with them in Canberra, Sydney and Melbourne.
Getting a Taxi by yourself in Sydney? - sit up front mate - love it!
-- Edited by longld on Wednesday 3rd of September 2014 05:48:33 AM
Hi guys,
This is the game we play here. The TGA have approved Sovaldi, so Gilead now try to get our Federal Government to pay for it, by putting it on our PBS (Pharmaceutical Benefits Scheme). So it's submitted to the PBAC, who refuse it. In 2 months, they'll do it again. Merck submitted Victrelis 12 times before it was approved.
There's a rumour that a deal has been done with AbbVie. If that's correct, we may get their trio of drugs at the 'right price', and Sovaldi will left out in the cold.
Well, they are only Australians, after all. As long as I get mine, right?
Looks like Sovaldi is too expensive for Australians according to the government?
http://www.gastroenterologyupdate.com.au/latest-news/sofosbuvir-and-vedolizumab-knocked-back